15 December 2022
SHARE NOW
Gene Therapy
GMP
Regulatory & Standards
Scaling Up
Viral/Non-Viral Vectors
Over the past year or so, the spotlight has been fixed on AAV as a promising opportunity for advancing gene therapy manufacture, but what challenges surround the manufacture of AAV, and how can novel technologies overcome these obstacles? Phacilitate Editor, Georgi Makin, explores this by putting ‘TESSA™ technology’ from OXGENE, a WuXi Advanced Therapies’ company, in the spotlight.
When it comes to manufacturing viral vectors, there remain a few challenges to be overcome to allow companies to produce batches large enough to satisfy clinical demand.
Enjoying this article? Download the full eBook, here >>
Up to now, plasmids have been the ‘gold standard’ for viral vector manufacture, providing robust manufacture of AAV for gene therapies currently in the pipeline. Plasmid engineering and robust transient manufacturing platforms have helped to ensure the success of AAV-based therapies so far but are not without their limitations.
THIS ARTICLE CONTINUES IN THE FULL EBOOK. DOWNLOAD IT HERE >>
This article has been produced in partnership with WuXi Advanced Therapies. 
More like this
Navigating the Applications of Title21’s Manufacturing Execution System
In this Tech Demo, Title21 describes how its Manufacturing Exertion System (MES), a powerful platform of integrated modules can supports and autologous and allogeneic workflows.
3 February 2023
ScaleReady Demonstrate Cue – A Platform for Small Volume Cell Processing
In this Tech Demo we are introduced to ScaleReady’s Cell Processing System Cue, it’s components and applications in small volume cell processing, as seen at Advanced Therapies Week 2023.
2 February 2023
NICE Approves CAR-T as NHS Treatment for Aggressive Forms of Blood Cancer
NICE has announced the approval of Kite’s CAR-T cell therapy Yescarta, for the treatment of patients with r/r DLBCL and PMBCL, who have already had two or more lines of systemic therapy.
1 February 2023
